Manages manifestations of psychotic disorders. ANDA 216678, held by Rubicon Research. Chlorpromazine Hydrochloride.
As of Nov 16, 2026, ANDA 216678 (Chlorpromazine Hydrochloride), held by Rubicon Research, was first approved by FDA on Oct 10, 2025, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 10, 2025 | Original application | Approved | None posted |
| Chlorpromazine Hydrochloride30MG/ML · concentrate;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride100MG/ML · concentrate;oral | Chlorpromazine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters